net dbt
investor agreement lead cost save
news board refresh commit margin expans
earlier morn announc enter agreement starboard
valu regard new valu creation opportun agreement includ
appoint four new member board director commit adjust
oper margin target creation
financ strategi committe overse oper improv initi
increas share repurchas author new board
director includ john greisch former president/ceo halsey
wise former chairman/ceo medasset melinda mount former presid
aliphcom inc georg riedel former chairman/ceo cloudmark inc
matter signific opportun valu creation
view today announc meaning posit develop
struggl improv margin market headwind help slow revenu
growth recent year previous wrote reinstat
takeaway analyst day long believ
increment opportun margin expans within cern drive
ep higher time combin larg contract veteran affair
next year see today announc creat increment support
stock reiter buy rate
increas ep expect cost cut
follow today announc increas ep
ep driven expect cost manag
follow today announc well increas contribut share
repurchas point refer new adjust oper margin
vs compani target oper margin improv
oper effici increas price object
repres ep ex-cash unchang previou target expect
manag address detail cost restructur plan upcom
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
largest stand-alone healthcar
compani sell wide rang softwar
servic hospit physician
product cerner millennium platform
serv base broader solut
offer also sell number addit
servic offer leverag clinic
infrastructur larg instal base
compani base kansa citi
buy rate base market leader
widest rang increment cross-sel
opportun within ever-grow custom
base compani also abl leverag
recent expens provid
increment cash flow appli
valuat overal market growth
slow vs post-american recoveri
reinvest act period see
continu share-gain becom
bifurc competit market
price object base ep estim previous
cy ex-cash multipl five-year averag absolut
multipl basi well rel incorpor modest growth
slowdown also premium market-lead posit
downsid risk po market paus spend particularli driven
healthcar reform uncertainti increas competit pressur epic system
well newer cloud-bas entiti integr cost associ va
dod contract hamper margin upsid risk would come acceler
cross-sel opportun notabl around popul health revenu upsid va
contract roll-out increas leverag drive improv margin expans potenti
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
